Julie Cherrington, Ph.D.

Julie joined the Mirati Board of Directors in 2019. Julie also serves on the board of QUE Oncology and Rakovina Therapeutics, Inc. She is an experienced life science executive with extensive insight in bringing drugs into the clinic and through to commercialization. She has been a key contributor to the successful development of multiple FDA-approved products, including Sutent,* Palladia,* Vistide,* Viread* and Hepsera.*

Julie most recently served as President and Chief Executive Officer of Arch Oncology, a clinical-stage immuno-oncology company developing novel anti-CD47 mAbs. Previously, she served as President and Chief Executive Officer at several other oncology companies, including Revitope Oncology, Zenith Epigenetics and Pathway Therapeutics, a company advancing targeted kinase inhibitors for the treatment of cancer. In addition, she served as President and Executive Vice President, R&D, at Phenomix Corporation. Earlier in her career, Julie was Vice President of Preclinical and Clinical Research at SUGEN, a Pharmacia/Pfizer company. She began her career at Gilead Sciences, where she held a range of positions of increasing responsibility.

Julie earned her Ph.D. in microbiology and immunology from the University of Minnesota and Stanford University. She completed a postdoctoral fellowship at the University of California, San Francisco. She holds her M.S. in microbiology and B.S. in biology from the University of California, Davis.

* Trademarks are property of their respective owners.

About Cookies on This Site

This website uses cookies. Essential and functional cookies are necessary for the proper functioning of this website and cannot be refused. Other cookies are used for statistical purposes and will only be placed if you agree to their placement. For further details on cookies, how we use cookies and how to modify your choices regarding cookies, please read our Cookies Policy.